Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 May;23(5):715–720. doi: 10.1128/aac.23.5.715

Susceptibility of bovid herpesvirus 1 to antiviral drugs: in vitro versus in vivo efficacy of (E)-5-(2-Bromovinyl)-2'-deoxyuridine.

L A Babiuk, S D Acres, V Misra, P H Stockdale, E De Clercq
PMCID: PMC184794  PMID: 6307134

Abstract

The relative efficacies of a variety of antiviral drugs against bovid herpesvirus 1 was investigated. (E)-5-(2-Bromovinyl)-2'-deoxyuridine and trifluorothymidine were found to be inhibitory at doses of 0.01 micrograms/ml in in vitro yield reduction and plaque reduction assays. In contrast, acylovir was inactive even at concentrations as high as 1,000 micrograms/ml. Other drugs, including phosphonoformic acid, 9-beta-D-arabinofuranosyladenine, 5-iodo-2-deoxyuridine, and 1-beta-D-arabinofuranosylcytosine were active at concentrations previously shown to inhibit herpes simplex virus. Oral administration of (E)-5-(2-bromovinyl)-2'-deoxyuridine to calves infected with bovid herpesvirus 1 had no effect on the level of virus shedding, clinical signs, or susceptibility to secondary bacterial infection with Pasteurella haemolytica. The reason for this lack of in vivo activity was that sufficient levels of the drug in blood were not achieved by oral administration.

Full text

PDF
715

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen L. B., Huffman J. H., Revankar G. R., Tolman R. L., Simon L. N., Robins R. K., Sidwell R. W. Efficacy of 9-beta-D-arabinofuranosylhypoxanthine 5'-monophosphate in therapy of equine abortion virus-induced hepatitis in hamsters. Antimicrob Agents Chemother. 1975 Oct;8(4):474–478. doi: 10.1128/aac.8.4.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ayisi N. K., Gupta V. S., Meldrum J. B., Taneja A. K., Babiuk L. A. Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1980 Apr;17(4):558–566. doi: 10.1128/aac.17.4.558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Babiuk L. A., Meldrum B., Gupta V. S., Rouse B. T. Comparison of the antiviral effects of 5-methoxymethyl-deoxyuridine with 5-iododeoxyuridine, cytosine arabinoside, and adenine arabinoside. Antimicrob Agents Chemother. 1975 Dec;8(6):643–650. doi: 10.1128/aac.8.6.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Babiuk L. A., Misra V. Levamisole and bovine immunity: in vitro and in vivo effects on immune responses to herpesvirus immunization. Can J Microbiol. 1981 Dec;27(12):1312–1319. doi: 10.1139/m81-201. [DOI] [PubMed] [Google Scholar]
  5. Babiuk L. A., Wardley R. C., Rouse B. T. Defense mechanisms against bovine herpesvirus: relationship of virus-host cell events to susceptibility to antibody-complement cell lysis. Infect Immun. 1975 Nov;12(5):958–963. doi: 10.1128/iai.12.5.958-963.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  7. Forman A. J., Babiuk L. A. Effect of infectious bovine rhinotracheitis virus infection on bovine alveolar macrophage function. Infect Immun. 1982 Mar;35(3):1041–1047. doi: 10.1128/iai.35.3.1041-1047.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Forman A. J., Babiuk L. A., Misra V., Baldwin F. Susceptibility of bovine macrophages to infectious bovine rhinotracheitis virus infection. Infect Immun. 1982 Mar;35(3):1048–1057. doi: 10.1128/iai.35.3.1048-1057.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hettinger M. E., Pavan-Langston D., Park N. H., Albert D. M., De Clercq E., Lin T. S. Ac2IDU, BVDU, and thymine arabinoside therapy in experimental herpes keratitis. Arch Ophthalmol. 1981 Sep;99(9):1618–1621. doi: 10.1001/archopht.1981.03930020492020. [DOI] [PubMed] [Google Scholar]
  10. Hill T. J., Blyth W. A., Harbour D. A. Recurrent herpes simplex in mice; topical treatment with acyclovir cream. Antiviral Res. 1982 Aug;2(3):135–146. doi: 10.1016/0166-3542(82)90015-8. [DOI] [PubMed] [Google Scholar]
  11. Jericho K. W., Yates W. D., Babiuk L. A. Bovine herpesvirus-1 vaccination against experimental bovine herpesvirus-1 and Pasteurella haemolytica respiratory tract infection: onset of protection. Am J Vet Res. 1982 Oct;43(10):1776–1780. [PubMed] [Google Scholar]
  12. Kern E. R., Glasgow L. A., Klein R. J., Friedman-Kien A. E. Failure of 2-deoxy-D-glucose in the treatment of experimental cutaneous and genital infections due to herpes simplex virus. J Infect Dis. 1982 Aug;146(2):159–166. doi: 10.1093/infdis/146.2.159. [DOI] [PubMed] [Google Scholar]
  13. Kern E. R., Overall J. C., Jr, Glasgow L. A. Herpesvirus hominis infection in newborn mice: comparison of the therapeutic efficacy of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyladenine. Antimicrob Agents Chemother. 1975 May;7(5):587–595. doi: 10.1128/aac.7.5.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Myers M. W., Glasgow L. A., Galasso G. J. From the National Institutes of Allergy and Infectious Diseases. Summary of a workshop on antiviral agents for genital herpesvirus infections. J Infect Dis. 1982 May;145(5):774–782. doi: 10.1093/infdis/145.2.774. [DOI] [PubMed] [Google Scholar]
  15. Overby L. R., Robishaw E. E., Schleicher J. B., Rueter A., Shipkowitz N. L., Mao J. C. Inhibition of herpes simplex virus replication by phosphonoacetic acid. Antimicrob Agents Chemother. 1974 Sep;6(3):360–365. doi: 10.1128/aac.6.3.360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pastoret P. P., Babiuk L. A., Misra V., Griebel P. Reactivation of temperature-sensitive and non-temperature-sensitive infectious bovine rhinotracheitis vaccine virus with dexamethasone. Infect Immun. 1980 Aug;29(2):483–488. doi: 10.1128/iai.29.2.483-488.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Reefschläger J., Brwolff D., Bärwolff D., Langen P., Rosenthal H. A. Efficiency and selectivity of (E)-5-(2-bromovinyl)-2'-deoxyuridine and some other 5-substituted 2'-deoxypyrimidine nucleosides as anti-herpes agents. Antiviral Res. 1982 May;2(1-2):41–52. doi: 10.1016/0166-3542(82)90025-0. [DOI] [PubMed] [Google Scholar]
  18. Richards J. T., Kern E. R., Overall J. C., Jr, Glasgow L. A. Anti-herpesvirus activity of adenine arabinoside analogues in tissue culture and a genital infection of mice and guinea pigs. Antiviral Res. 1982 May;2(1-2):27–39. doi: 10.1016/0166-3542(82)90024-9. [DOI] [PubMed] [Google Scholar]
  19. Rouse B. T., Babiuk L. A. Host defense mechanisms against infectious bovine rhinotracheitis virus: in vitro stimulation of sensitized lymphocytes by virus antigen. Infect Immun. 1974 Oct;10(4):681–687. doi: 10.1128/iai.10.4.681-687.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Schnipper L. E., Crumpacker C. S. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2270–2273. doi: 10.1073/pnas.77.4.2270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Selby P. J., Powles R. L., Janeson B., Kay H. E., Watson J. G., Thornton R., Morgenstern G., Clink H. M., McElwain T. J., Prentice H. G. Parenteral acyclovir therapy for herpesvirus infections in man. Lancet. 1979 Dec 15;2(8155):1267–1270. doi: 10.1016/s0140-6736(79)92281-5. [DOI] [PubMed] [Google Scholar]
  22. Weinmaster G. A., Misra V., McGuire R., Babiuk L. A., DeClercq E. Bovid herpesvirus type-1 (infectious bovine rhinotracheitis virus)-induced thymidine kinase. Virology. 1982 Apr 15;118(1):191–201. doi: 10.1016/0042-6822(82)90332-4. [DOI] [PubMed] [Google Scholar]
  23. de Clercq E., Verhelst G., Descamps J., Bergstrom D. E. Differential inhibition of herpes simplex viruses, type 1 (HSV-1) an type 2 (HSV-2), by (E)-5-(2-X-vinyl)-2'-deoxyuridines. Acta Microbiol Acad Sci Hung. 1981;28(3):307–312. [PubMed] [Google Scholar]
  24. de Clercq E., Zhang Z. X., Sim I. S. Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice. Antimicrob Agents Chemother. 1982 Sep;22(3):421–425. doi: 10.1128/aac.22.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES